Asset Details
Do you wish to reserve the book?
Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus
Do you wish to request the book?
Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus
2025
Overview
To explore the potential efficacy of early initiation of intravenous cyclophosphamide (IVCPA), we reviewed consecutive four cases of super‐refractory cryptogenic‐new onset refractory status epilepticus (C‐NORSE) between 2015 and 2023. We compared functional outcomes at 3 months and 1 year after the onset between patients who received IVCPA within 20 days (early‐treated) and those who received it later (late‐treated). All patients (median age: 43 years) had a prodromal fever. Brain MRI revealed symmetrically increased FLAIR signals in the medial temporal lobes of all patients. Despite initiating antiseizure medications (ASMs) and first‐line immunotherapy (intravenous‐methylprednisolone and immunoglobulins) within a median of 3 days from onset, SE persisted >5 days. The diagnosis of C‐NORSE was suggested based on a high C‐NORSE score (6/6). Thus, all patients received IVCPA a median of 15.5 days after seizure onset (three within 20 days and one at 31 days). One of the three early‐treated patients also received tocilizumab. Early‐treated patients exhibited shorter sedation periods (median 29 vs. 75 days) and better 1 year functional status (mRS 1–2 vs. mRS 4) compared to the late‐treated patient. Early initiation of IVCPA and/or tocilizumab, along with ASMs, may contribute to a better one‐year functional status in super‐refractory C‐NORSE patients. Plain Language Summary This study demonstrates the potential efficacy of early administration of intravenous cyclophosphamide on one‐year functional status in patients with super‐refractory cryptogenic‐new onset refractory status epilepticus. “Early‐treated patients” who received it within 20 days of seizure onset achieved a good one‐year functional status. The “late‐treated patient” (Case 4) who received it later did not achieve a good functional status. Early initiation of cyclophosphamide, along with antiseizure medications, may contribute to a better one‐year functional status in this population.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Adult
/ Anticonvulsants - therapeutic use
/ Antigens
/ Cyclophosphamide - administration & dosage
/ Cyclophosphamide - therapeutic use
/ Delirium
/ Drug Resistant Epilepsy - diagnostic imaging
/ Drug Resistant Epilepsy - drug therapy
/ Etiology
/ Female
/ Humans
/ Immunosuppressive Agents - administration & dosage
/ Immunosuppressive Agents - therapeutic use
/ Male
/ NORSE
/ Patients
/ Short
/ Status Epilepticus - diagnostic imaging
